KYMR - Latest News
Kymera Therapeutics, Inc. (KYMR), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $9.66B. Beta to the broader market is 1.95.
The article list below shows the most recent KYMR headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent KYMR Headlines
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
zacks.com - Aug 6, 2026
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-e
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
seekingalpha.com - Aug 5, 2026
Kymera Therapeutics, Inc.
Kymera Therapeutics Q2 Earnings Call Highlights
marketbeat.com - Aug 5, 2026
Kymera Therapeutics NASDAQ: KYMR said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, po
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
zacks.com - Aug 5, 2026
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
globenewswire.com - Aug 5, 2026
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026
How News Affects KYMR Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track KYMR's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked KYMR news questions
- What is the latest KYMR news headline?
- The most recent KYMR headline (Aug 6, 2026) is "KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the KYMR news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What KYMR news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual KYMR options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.